Cancer Drug THIO Traps Telomerase in Dead-End Complex to Stop Tumor Growth
Scientists reveal exactly how the cancer drug 6-thio-dG halts telomere elongation—locking telomerase in a non-productive stall rather than ejecting it.
Summary
Researchers have uncovered the precise molecular mechanism by which 6-thio-deoxyguanosine (6-thio-dG, also called THIO) inhibits telomerase in cancer cells. Rather than simply blocking the enzyme or causing it to fall off telomeres, 6-thio-dG is incorporated into telomeric DNA and then traps telomerase in a non-productive stalled complex after translocation—preventing new repeat additions. Cancer cells with shorter telomeres proved more sensitive to the drug, experiencing greater telomere loss. These findings clarify why THIO selectively harms telomerase-expressing cancer cells while sparing most normal cells, and support its continued development as a precision anti-cancer therapeutic.
Detailed Summary
Telomerase is upregulated in over 85% of cancers, enabling unlimited cell division by continuously replenishing telomeric DNA lost during replication. Because most healthy somatic cells lack telomerase activity, the enzyme represents an attractive selective cancer target. The drug 6-thio-2'-deoxyguanosine (6-thio-dG / THIO) had shown preclinical promise in melanoma, lung cancer, glioblastoma, and pediatric brain tumors, and synergizes with immune checkpoint inhibitors—but its precise mechanism of action against telomerase remained poorly defined.
This study used a combination of direct biochemical telomerase activity assays, single-molecule imaging, cell-based telomere length analyses (FISH, TRF), and iPSC models to dissect how 6-thio-dG disrupts telomerase function. The key finding is that telomerase readily incorporates 6-thio-dGTP into the growing telomeric strand—with catalytic efficiency nearly identical to natural dGTP—but once inserted, the modified nucleotide blocks the repeat addition processivity (RAP) step. Crucially, this block occurs specifically after translocation: telomerase completes one repeat, repositions along its product DNA to re-align the RNA template, and then stalls in a non-productive complex rather than dissociating from the telomere. The processivity factors POT1-TPP1, which normally stimulate RAP, could not rescue this inhibition.
Single-molecule experiments provided direct evidence that 6-thio-dG-stalled telomerase remains bound to the telomeric DNA substrate, occupying the telomere without extending it—a 'dead-end' complex. Cell-based experiments confirmed that 6-thio-dG treatment inhibits telomere synthesis by telomerase in living cancer cells. Importantly, cancer cells harboring critically short telomeres (which depend most urgently on telomerase activity) were significantly more sensitive to 6-thio-dG and showed greater induction of telomere losses and DNA damage signaling at telomeres (DDR+ telomeres), compared to cancer cells with longer telomere reserves.
The implications are notable for therapeutic selectivity: cancer cells typically undergo extensive telomere shortening before telomerase is reactivated, meaning they carry shorter telomeres than normal cells. Transient telomerase inhibition via 6-thio-dG should therefore deplete telomeres more rapidly in cancer cells, while normal telomerase-negative somatic cells are largely unaffected. An iPSC model expressing telomerase also validated that the drug's effects are telomerase-dependent.
Caveats include that the study is largely biochemical and cell-based; in vivo pharmacokinetics, off-target effects on genomic DNA replication, and long-term tumor resistance mechanisms require further investigation. The drug's behavior in ALT-pathway cancers (which lack telomerase) and in tissues with physiological telomerase expression (e.g., stem cells) also warrant careful evaluation before broader clinical translation.
Key Findings
- 6-thio-dGTP is incorporated by telomerase with near-normal efficiency but blocks repeat addition processivity (RAP) after translocation.
- Telomerase stalls in a non-productive complex on telomeric DNA rather than dissociating—a mechanistically distinct inhibition mode.
- Processivity cofactors POT1-TPP1 cannot rescue 6-thio-dG-induced telomerase stalling.
- Cancer cells with critically short telomeres are more sensitive to 6-thio-dG and show greater telomere loss.
- Cell-based experiments provide direct evidence that 6-thio-dG suppresses telomerase-mediated telomere synthesis in live cancer cells.
Methodology
The study employed direct biochemical telomerase activity assays with radiolabeled primers and physiologic dNTP concentrations, single-molecule fluorescence imaging to track telomerase binding dynamics, and cell-based assays including telomere FISH, TRF Southern blotting, and immunofluorescence for DDR markers across multiple cancer cell lines and iPSC models.
Study Limitations
The mechanistic data are primarily biochemical and cell-culture based; in vivo pharmacokinetics, potential incorporation into genomic DNA by replicative polymerases, and long-term resistance mechanisms are not fully characterized. Effects on physiologically telomerase-active normal tissues (e.g., hematopoietic stem cells) require further study before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: